<DOC>
	<DOCNO>NCT02788578</DOCNO>
	<brief_summary>The objective PRELUDE study describe use lanreotide Autogel® ( LAN ATG ) combine Peptide Receptor Radionuclide Therapy ( PRRT ) treatment progressive neuroendocrine tumour locate lung digestive system currently limit data treatment use together types neuroendocrine tumour .</brief_summary>
	<brief_title>A Retrospective Data Analysis Therapy With PRRT Combined With Lanreotide Autogel® Neuroendocrine Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Histopathologically confirm metastatic well differentiated Neuroendocrine Tumour ( NET ) ( Grade G1 G2 accord World Health Organisation 2010 classification ) : Gastroenteropancreatic ( GEP ) Bronchopulmonary ( BP ) primary tumour , tumour unknown origin believe GEP origin , primary tumour elsewhere exclude multiphasic computerise tomography ( CT ) magnetic resonance imaging ( MRI ) Disease progression radiologically document evaluable imaging ( CT MRI , digital printout ) , perform within 12 month within 6 month prior first PRRT/LAN ATG cycle Metastatic locallyadvanced , hormonal functioning nonfunctioning GEPNET BPNET ; Confirmed presence Somatostatin Receptors ( SSTRs ) target lesion base positive SSTR scintigraphy ( Octreoscan®/99mTCtektrotyd ) 68Ga SSTR Positron Emission TomographyComputerised Tomography ( PET/CT ) imaging , i.e . Grade ≥2 respectively per Krenning scale per modify Krenning scale Absence information regard LAN ATG treatment : dose receive , start date , frequency injection No CT MRI within 12 month within 6 month precede baseline , end last PRRT/LAN ATG cycle Absence information cumulative activity PRRT 177 Lutetium ( 177Lu ) DOTATOC 177LuDOTATATE receive ( least 500 mCi ( equivalent 18.5 GBq ) , entire therapy ) PRRT prior first combination cycle PRRT/LAN ATG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>